Overview

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate dose limiting toxicity (DLT), investigate the tolerability and safety of eribulin mesylate with trastuzumab combination therapy, and estimate the recommended dose.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Mitogens
Trastuzumab